Case Number:

PGR2021-00030

Case Type:

PGR

Status:

Trial Instituted

Petitioner:

Daiichi Sankyo, Inc. et al.

1. Filed: December 23, 2020 00:00

   Coverage

   1. January 17, 2024

      PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict

      The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi infringed in a $42 million verdict in 2022, were invalid.

   5 other articles on this case. View all »

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login